Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group LSE:RENE London Ordinary Share GB00B0DZML60 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.05p +3.03% 1.70p 1.65p 1.75p 1.70p 1.65p 1.65p 1,737,014 11:46:12
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -18.2 -0.5 - 53.80

Reneuron Share Discussion Threads

Showing 5451 to 5472 of 5475 messages
Chat Pages: 219  218  217  216  215  214  213  212  211  210  209  208  Older
DateSubjectAuthorDiscuss
18/9/2017
16:13
Is everything a buy today I wonder?
small crow
07/9/2017
11:29
Woodford apologising for his poor investment performance over the last year! Apparently we need to avoid being distracted by "the mist on an October morning"! Story in Telegraph business section today... That said, lots of potential here....but it's definitely a waiting game and likely a bumpy Road as trials data emerge.
audigger
06/9/2017
11:52
Yes, good positive news. Pity the investment market is so short sighted and thank goodness we have Neil Woodford and Chris Evans onboard. Next 4 month's should deliver significant news flow. Best wishes. Freddie
fredd1eboy
06/9/2017
07:29
Reading through the AGM report there is so much potential here, especially in the blindness treatments which could be up and running relatively quickly and would be life-changing for sufferers. The exosome work is distantly blue-sky, but the focus on solid tumours, hard to treat conventionally but very common, could pay massively if it works. Not one for the day-traders but 2-5 years could see a massive re-rate.
small crow
05/9/2017
10:27
IMMUPHARMA (IMM) Potential blockbuster Lupuzor Phase III results due Q1 2018. Only other similar drug Benlysta was bought out from HGSi by GSK in 2012 for $3.6 billion for 50% stake valuing Benlysta around $7 billion (and IMM's Lupuzor appears to be safer and more efficaceous than Benlysta). $7 billion buyout of IMM gives £39.70 share price against current 54p, or 70+ bagger !!! Potential blockbuster Lupuzor has 'Fast Track' and 'SPA' status from US FDA, so could market launched in 2018. Tim McCarthy (IMM's Chairman) 14/3/2017: "There's going to be a fantastic return on investment for anybody who invests in ImmuPharma...This (Lupuzor) is going to be a multi-billion dollar drug, its as simple as that...This will absolutely be a multi-billion dollar drug." 4 min 40 sec. hTTps://www.youtube.com/watch?v=M5Af_uSSXTM
top tips
03/9/2017
18:31
Interesting have a few of these. Anyway fed up grubbing for money. Off to the highlands Stalking for a week and Singapore Grand Prix next week. I'm sure nothing exciting shall happen in the interim.
yachtmaster2
03/9/2017
13:44
... and with Nasdaq listing experience.
small crow
03/9/2017
12:10
Hmmmm. M&A expert brought in.....
bigspuds
29/8/2017
11:41
IMMUPHARMA (IMM) Potential blockbuster Lupuzor Phase III results due Q1 2018. Tim McCarthy (IMM's Chairman) 14/3/2017: "There's going to be a fantastic return on investment for anybody who invests in ImmuPharma...This (Lupuzor) is going to be a multi-billion dollar drug, its as simple as that...This will absolutely be a multi-billion dollar drug." 4 min 40 sec. hTTps://www.youtube.com/watch?v=M5Af_uSSXTM
top tips
22/8/2017
18:57
http://citywire.co.uk/investment-trust-insider/news/sphere-tumbles-after-pinning-hopes-on-woodford-rescue/a1043359?ea=294204&re=48726&utm_source=BulkEmail_Investment+Trust+Insider+Weekly&utm_medium=BulkEmail_Investment+Trust+Insider+Weekly&utm_campaign=BulkEmail_Investment+Trust+Insider+Weekly
dickbush
08/8/2017
14:46
Long way to go yet for me to get my money back...
stewart_25
08/8/2017
09:37
The strength here continues. It doesn't matter that products and profit might be some way off (pace Amazon, Facebook, etc etc etc) with this kind of co the valuation is all about the potential and, as Woodford notes, there is a great deal in this technology.
small crow
07/8/2017
15:55
Anyone going to the AGM next Month? 06/09/17 London. Freddie? Anyone?
algernon2
07/8/2017
09:55
I agree with Woodford on the potential for Reneuron but the rationale makes no sense. These guys are burning cash at ~£13m per year and their therapeutic candidates are nowhere near the clinic. So the market is discounting this. The fact that they have £54m cash just means they've got ~ 4 years, at this rate of cash burn, to progress the technology. That said, if this thing was listed in the US, I expect it would be worth 10 x the current market cap, given how exciting and world-leading the technology is and how US investors tend to have more risk appetite for innovation. One for the very long-term. 2p very attractive levels!
rrb
07/8/2017
09:45
Ze Germans always state the bleeding obvious! Now they're trying to steal our shares.
alphapig
07/8/2017
09:22
"mkt cap equals cash on balance sheet" - That's as at today. Henceforth for the immediate future money is going out and none coming in! - So as always you pays your money and takes your chance!
deutsch3
07/8/2017
08:29
Good write up by Woodford mkt cap equals cash on balance sheet
nw99
07/8/2017
08:22
Someone likes
richtea2517
07/8/2017
07:37
Time to buy?
rayrac
06/8/2017
13:17
I seem to remember the cash was raised in a big share issue and is needed to progress the drugs through development and trials, so its a diminishing cash pile rather than something built up from commercial revenues. No position here at present.
deccer1
06/8/2017
11:19
Spot on nw
fredd1eboy
06/8/2017
08:53
Interesting cash on Bal sheet = mkt cap could be a big winner
nw99
Chat Pages: 219  218  217  216  215  214  213  212  211  210  209  208  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170921 05:17:46